AU2016201382A1 - Methods for improving cognitive function and decreasing heart rate - Google Patents

Methods for improving cognitive function and decreasing heart rate Download PDF

Info

Publication number
AU2016201382A1
AU2016201382A1 AU2016201382A AU2016201382A AU2016201382A1 AU 2016201382 A1 AU2016201382 A1 AU 2016201382A1 AU 2016201382 A AU2016201382 A AU 2016201382A AU 2016201382 A AU2016201382 A AU 2016201382A AU 2016201382 A1 AU2016201382 A1 AU 2016201382A1
Authority
AU
Australia
Prior art keywords
dha
subject
acid
dosage form
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016201382A
Other languages
English (en)
Inventor
Karin Yurko-Mauro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010207929A external-priority patent/AU2010207929B2/en
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to AU2016201382A priority Critical patent/AU2016201382A1/en
Publication of AU2016201382A1 publication Critical patent/AU2016201382A1/en
Priority to AU2017245327A priority patent/AU2017245327A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2016201382A 2009-02-02 2016-03-03 Methods for improving cognitive function and decreasing heart rate Abandoned AU2016201382A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016201382A AU2016201382A1 (en) 2009-02-02 2016-03-03 Methods for improving cognitive function and decreasing heart rate
AU2017245327A AU2017245327A1 (en) 2009-02-02 2017-10-10 Methods for improving cognitive function and decreasing heart rate

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US61/149,310 2009-02-02
US18354809P 2009-06-02 2009-06-02
US61/183,548 2009-06-02
AU2010207929A AU2010207929B2 (en) 2009-02-02 2010-02-02 Methods for improving cognitive function and decreasing heart rate
AU2016201382A AU2016201382A1 (en) 2009-02-02 2016-03-03 Methods for improving cognitive function and decreasing heart rate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2010207929A Division AU2010207929B2 (en) 2009-02-02 2010-02-02 Methods for improving cognitive function and decreasing heart rate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017245327A Division AU2017245327A1 (en) 2009-02-02 2017-10-10 Methods for improving cognitive function and decreasing heart rate

Publications (1)

Publication Number Publication Date
AU2016201382A1 true AU2016201382A1 (en) 2016-03-24

Family

ID=42041547

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016201382A Abandoned AU2016201382A1 (en) 2009-02-02 2016-03-03 Methods for improving cognitive function and decreasing heart rate
AU2017245327A Abandoned AU2017245327A1 (en) 2009-02-02 2017-10-10 Methods for improving cognitive function and decreasing heart rate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017245327A Abandoned AU2017245327A1 (en) 2009-02-02 2017-10-10 Methods for improving cognitive function and decreasing heart rate

Country Status (8)

Country Link
US (2) US20100203123A1 (enExample)
EP (2) EP2939671A1 (enExample)
JP (5) JP2012516852A (enExample)
CN (3) CN104042600A (enExample)
AU (2) AU2016201382A1 (enExample)
CA (1) CA2751275A1 (enExample)
HK (1) HK1202243A1 (enExample)
WO (1) WO2010088700A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
WO2012159092A2 (en) * 2011-05-19 2012-11-22 The Regents Of The University Of California Medical food for cognitive decline
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US9446141B2 (en) * 2013-03-15 2016-09-20 Genspera, Inc. Methods of producing cancer compounds
BR112016014262B1 (pt) 2013-12-20 2022-04-05 MARA Renewables Corporation Método para recuperar lipídeos de uma população de micro-organismos
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
AU2020325063B2 (en) * 2019-08-08 2026-04-02 Swinburne University Of Technology Uses of long-chain polyunsaturated fatty acids
IL297000A (en) 2020-04-03 2022-12-01 Mara Renewables Corp Microbial oils with high levels of omega-3 fatty acids
DE102020115238A1 (de) * 2020-06-09 2021-12-09 Pm-International Ag Nahrungsergänzungsmittel und Nahrungsmittel
KR20220167321A (ko) * 2020-07-02 2022-12-20 페어 테라퓨틱스 (유에스), 인코포레이티드 디지털 치료 위약 및 샴을 생성 및 관리하기 위한 시스템, 방법 및 디바이스
CA3204546A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment
WO2024155781A1 (en) * 2023-01-18 2024-07-25 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein
WO2025019424A1 (en) * 2023-07-14 2025-01-23 Dsm Ip Assets B.V. Microbial oils having high epa content and methods of making the same
WO2025100476A1 (ja) * 2023-11-10 2025-05-15 国立大学法人京都大学 生理機能改善用の組成物
JP2025079778A (ja) * 2023-11-10 2025-05-22 ダイドーグループホールディングス株式会社 生理機能改善用の組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
ES2135756T3 (es) 1994-08-16 1999-11-01 Frische Gmbh Procedimiento para la obtencion de productos nativos no solubles en agua a partir de mezclas de sustancias con ayuda de la fuerza centrifuga.
WO1996033263A1 (en) * 1995-04-17 1996-10-24 JAPAN, represented by DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
DE60012934T2 (de) 1999-02-26 2005-08-25 Martek Biosciences Corp. Verfahren zum Abtrennen von einem Docosahexaensäure enthaltenden Triglycerid aus einem Triglyceridgemisch
US6395778B1 (en) * 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
KR101591834B1 (ko) 2000-01-19 2016-02-18 마텍 바이오싸이언스스 코포레이션 무용매 추출 방법
ATE395835T1 (de) 2000-04-12 2008-06-15 Westfalia Separator Gmbh Verfahren zur fraktionierung von öl- und polar lipid-enthaltenden rohstoffen
EP1392278A4 (en) 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPIDREICH FRACTION WITH STEARIDONIC ACID AND GAMMA LINOLIC ACID FROM PLANT SEEDS AND MICROBES
EP1392623A4 (en) 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US9101151B2 (en) 2002-05-03 2015-08-11 Dsm Ip Assets B.V. High-quality lipids produced by enzymatic liberation from biomass
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1845999A4 (en) * 2005-01-24 2010-09-22 Pronova Biocare As USE OF A DHA-CONTAINING FATTY ACID COMPOSITION FOR THE PRODUCTION OF A PHARMACEUTICAL OR FOOD PRODUCT FOR THE TREATMENT OF AMYLOSIS RELATED DISEASES
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
KR20130101596A (ko) * 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
US20090023808A1 (en) 2007-06-29 2009-01-22 Martek Biosciences Corporation Production and Purification of Esters of Polyunsaturated Fatty Acids
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Also Published As

Publication number Publication date
AU2010207929A1 (en) 2011-09-22
CN108324706A (zh) 2018-07-27
JP2018104477A (ja) 2018-07-05
EP2939671A1 (en) 2015-11-04
CN104042600A (zh) 2014-09-17
CA2751275A1 (en) 2010-08-05
JP2012516852A (ja) 2012-07-26
WO2010088700A1 (en) 2010-08-05
US20130172412A1 (en) 2013-07-04
US20100203123A1 (en) 2010-08-12
AU2017245327A1 (en) 2017-11-02
EP2391361A1 (en) 2011-12-07
HK1202243A1 (en) 2015-09-25
CN102365087A (zh) 2012-02-29
JP2015143248A (ja) 2015-08-06
JP2020050675A (ja) 2020-04-02
JP2022059063A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
EP2939671A1 (en) Methods for improving cognitive function and decreasing heart rate
US11413263B2 (en) Reducing the risk of pathological effects of traumatic brain injury
JP6419927B2 (ja) 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
US20100130608A1 (en) Compositions and methods for reducing triglyceride levels
US20110086914A1 (en) Methods for Treating Traumatic Brain Injury
WO2010147994A1 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
US20110082205A1 (en) Docosahexaenoic Acid Gel Caps
HK1172241B (en) Reducing the risk of pathological effects of traumatic brain injury
HK1172241A (en) Reducing the risk of pathological effects of traumatic brain injury

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted